EXHIBIT 10

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

LICENSE AGREEMENT

          This Agreement is entered into as of December 3, 2002 (the “Effective
Date”), by and between Mixture Sciences, Inc. (“Licensee”), and Astral, Inc., a
Delaware corporation (“Licensor”).

          1.     Definitions.

                  “Intellectual Property” means all types of intellectual
property including, without limitation, inventions, pending patent applications,
issued patents, divisions, continuations, continuations-in-part, reissues,
provisionals, re-examinations, extensions, corresponding foreign rights,
copyrights, know-how, trade secrets, software programs, data, reports and
confidential information.

                  “Licensed Product” means any product which cannot be made,
used or sold without infringing on the patent rights contained in the Subject
Technology.

                  “Net Sales” means the gross amounts received by the Licensee
or its sublicensees on sales of Licensed Products, less:

                  a.     Customary trade, quantity or cash discounts and
non-affiliated brokers’ or agents’ commissions actually allowed and taken;

                  b.     Amounts repaid or credited by reason of rejection or
return; and/or

                  c.     To the extent separately stated on purchase orders,
invoices or other documents of sales, (i) taxes levied on and/or other
governmental charges made as to production, sale, transportation, delivery or
use and paid by or on behalf of Licensee or its sublicensees, and
(ii) transportation and transit insurance charges.

                  “Subject Technology” means the technology and inventions
described in the issued patents and pending patent applications identified on
Exhibit A attached hereto, together with all Intellectual Property related
thereto, and as further described in Licensor’s Business Plan (draft dated
10/29/02).

          2.     License Rights.

                  a.     Grant.  Licensor hereby grants to Licensee the
exclusive license right to use the Subject Technology, including, without
limitation, the right to make, have made, use, offer for sale, sell, and import
any and all products, methods and services utilizing the Subject Technology
and/or the Intellectual Property applicable to the Subject Technology.  Said
rights are worldwide, royalty-bearing, perpetual (subject to Section 5a), and
for all possible fields of use.  Licensee shall have the right to grant
sublicenses hereunder, including successive sub-sub-license grants.

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                  b.     Grant-Back. Licensee hereby grants back to Licensor the
right to use the Subject Technology for the limited purpose of performing and
implementing the mutually approved Project Plan (referenced in Section 3b),
until September 1, 2003.

          3.     Royalties.

                  a.     Earned Royalties.  Licensee shall pay earned royalties
to Licensor equal to ***** percent (*****%) of the Net Sales, subject to the
provisions set forth in Section 3A.

                  b.     Prepayments.  Licensee shall make prepayment advances
to Licensor of up to $***** (the “Prepayments”) for Licensor to use said funds
to pay for expenses summarized on Exhibit B, which expenses are for implementing
a project plan (the “Project Plan”) to further enhance the Subject Technology. 
Licensor and Licensee shall mutually prepare and approve said Project Plan by
December 14, 2002.  Licensor shall submit to Licensee a request for each
Prepayment, accompanied by a detailed description of the expenses for the
Project Plan which will be paid with the funds from the Prepayment.  Licensor
has the option and discretion to request less than the full $***** of
Prepayments.  Licensee shall advance the requested Prepayments to Licensor
within five (5) business days after the request is received by Licensee, so long
as the request is consistent with the Project Plan and Licensor is in full
compliance under all of the provisions, representations, warranties and
covenants of this Agreement, and Licensee is reasonably satisfied with the
progress being made by Licensor under Section 3A(a).

                  c.     Credits.  All Prepayments shall constitute prepayments
to be credited against the earned royalties, once earned royalties become due,
on a dollar-for-dollar basis.  If the ultimate earned royalties are less than
the aggregate of the Prepayments, then no refund will be owed by Licensor to
Licensee.

                  d.     Payment Schedule.  From and after the date when
Licensee (or its sublicensee) first sells Licensed Products, Licensee shall give
to Licensor an annual written report of Net Sales for each calendar year, which
report shall be due by March 31 of the following year.  All royalties payable
pursuant to Section 3a (less credits pursuant to Section 3c) shall be paid at
the same time as the annual report of Net Sales is given.

                  e.     Dollar Payments.  All payments due hereunder shall be
paid in United States Dollars.  If any currency conversion shall be required in
connection with any payment hereunder, such conversion shall be made by using
the exchange rate for the purchase of United States Dollars reported by the Wall
Street Journal on the last business day of the calendar year to which such
payments relate. 

                  f.     Record Keeping.  Licensee and its sublicensees shall
maintain complete and accurate books of account and records showing all sales of
Licensed Products.  For purposes of verifying the accuracy of the royalties paid
by Licensee pursuant to which Agreement, such books and records shall be open to
inspection and copying, during usual business hours, upon reasonable advance
notice, by an independent certified public accountant or by employees of
Licensor.  In the event that any such inspection shows any underreporting and
underpayment by Licensee in excess of five percent (5%) for any twelve (12)
month period, then Licensee shall

2

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

pay the cost of such examination.  Such books and records shall be maintained
for at least three (3) full years after the applicable sale.

          3A.  Third Party Licenses.

                  a.     With respect to the third party license agreements
referenced on Exhibit A, pursuant to which Licensor obtains license rights to
some of the Subject Technology (the “Third Party Licenses”), Licensor shall use
reasonable best efforts to obtain and maintain the Third Party Licenses in good
standing, and to obtain any necessary consents, if any, for the grant of the
license rights to Licensee pursuant to this Agreement.

                  b.     With respect to any payments to be made under the Third
Party Licenses (e.g., milestone fees, maintenance fees, royalties, etc., the
“Third Party Payments”), either Licensor shall pay the same, or if Licensee is
obligated to pay any of the Third Party Payments, then said payments shall
constitute credit offsets against the sums otherwise payable by Licensee to
Licensor (including without limitation the payment of royalties pursuant to
Section 3a above).

                  c.     If Licensor has not been able to obtain any necessary
consents under the Third Party Licenses by March 1, 2003, then at the option of
Licensee, Licensee is entitled to acquire 100% of the ownership of Licensor,
lien free, in consideration of Licensee agreeing to pay to the owner of Licensor
(Alliance Pharmaceutical Corp.) the same earned royalties which Licensee is
otherwise obligated to pay in the future to Licensor under this Agreement. 
Provided, however, if Licensee so elects to acquire the stock of Licensor, then
Licensor shall have the option to void said election by paying to Licensee the
cash Break-up Fee (defined in Section 5a) within 20 days after Licensor receives
the written notice of Licensee’s election to acquire Licensor’s stock.

                  d.     Licensor and Alliance Pharmaceutical Corp. hereby
warrant and represent (i) that the only significant assets of Licensor are the
Exhibit A Subject Technology, (ii) that the only significant obligations or
liabilities of Licensor are those contained in the Third Party Licenses, and
(iii) that Alliance Pharmaceutical Corp. is the sole owner of the Licensor.

                  e.     Alliance Pharmaceutical Corp. hereby covenants to
obtain a release of any liens on the stock of Licensor in the event Licensee
exercises its right to acquire the stock of Licensor.

          4.     Management of Patent Matters.  Until September 1, 2003,
Licensor shall manage the patent prosecution and maintenance matters applicable
to the Subject Technology, and Licensor shall keep Licensee fully informed as to
said matters.  After September 1, 2003, Licensee shall have the exclusive right
and authority to manage and handle all matters applicable to the prosecution,
maintenance and enforcement of the patent rights, pending patent applications
and future patent applications applicable to the Subject Technology.  This right
shall include Licensee selecting the patent attorney to handle said patent
matters, and making the management decisions as to whether to pursue litigation
to enforce any potential infringements against the patent rights.  Licensor
hereby grants to Licensee an irrevocable power of attorney for Licensee to take
all actions in the name of Licensor with respect to these patent management
matters.

3

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Additionally, Licensor hereby agrees to sign such additional papers as may be
necessary or appropriate to enable Licensee to effectively handle and manage
these patent management matters.  Licensee shall keep Licensor informed as to
what is happening and what Licensee is doing with respect to these patent
management matters.  After September 1, 2003, Licensee shall bear all costs and
expenses applicable to these patent management matters.  Any recovery realized
from prosecuting patent infringement claims applicable to the licensed patent
rights shall belong solely to Licensee.

          5.     Break-up Fee.

                  a.     Licensor and Licensee intend to pursue future
discussions for a possible joint venture company (the “Newco Venture”) involving
the Subject Technology and other proprietary technology belonging to Licensee. 
If mutual agreement for the Newco Venture has not been reached by June 1, 2003,
then either Licensee or Licensor may elect to terminate this Agreement,
whereupon Licensor shall pay to Licensee a break-fee equal to ***** times the
aggregate amount of the Prepayments which Licensee has paid to Licensor (the
“Break-up Fee”).  Either party may exercise said termination election up until
September 1, 2003 by giving written notice of the election to the other party. 
If Licensor is electing to terminate, then said election may be given and shall
be effective only if the election is accompanied by the full payment of the
Break-up Fee, payable by bank certified check, bank cashier’s check, or wire
transfer of good funds.  If Licensee is electing to terminate, then Licensor
shall pay the Break-up Fee within ten (10) business days after the termination
notice is given to Licensor.  If the termination election is not exercised as
set forth above by September 1, 2003, then neither party shall thereafter have
any right of termination under this Section 5a.  If this Agreement is so
terminated, then any sublicense granted under this Agreement shall also
terminate.

                  b.     The parties intend this Agreement to be a bona fide
license agreement, which has been negotiated on an “arm’s length” basis, with
reasonable and fair economic terms.  The parties do not intend this Agreement to
be construed or characterized as a loan agreement.  Licensor hereby grants to
Licensee a security interest in all of the Subject Technology, as collateral
security for the performance of Licensor’s obligation to pay the full amount of
the Break-up Fee if this Agreement is terminated pursuant to Section 5a, and/or
if this Agreement is somehow construed or recharacterized as a loan agreement,
or a line-of-credit agreement, or a promissory note, or some other credit
facility.  Licensee shall be entitled to exercise all rights permitted for a
secured party by the California Commercial Code.  Licensee shall be entitled to
file a customary UCC-1 Financing Statement with the appropriate State agencies,
and Licensor and Licensee shall file with the U.S. Patent and Trademark Office a
customary notice of Licensee’s interests as set forth in this Agreement.

                  c.     If the parties do mutually agree to proceed with the
Newco Venture, then no Break-up Fee will be payable by Licensor to Licensee.  As
part of the Newco Venture, as consideration for Licensee contributing to the
Newco Venture the rights granted to Licensee under this Agreement, either
(i) Licensee will be given by the Newco Venture an equity interest in Newco
equal to the Break-up Fee, or (ii) Licensee will be paid by the Newco Venture a
cash sum equal to the Break-up Fee, with Licensee to elect between (i) and
(ii).  Additionally,

4

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Licensee will obtain such additional equity interests in the Newco Venture for
Licensee’s other contributions as the parties may mutually agree.

                  d.     Notwithstanding the parties’ intent that this Agreement
is not to be construed as a loan agreement, if a court were to ultimately treat
this Agreement as a loan agreement, then the parties hereby acknowledge and
agree that such loan agreement is exempt from California usury laws by reason of
California Corporations Code Section 25118.  Further, if a court were to
ultimately treat this Agreement as a loan agreement and to not apply a usury
exemption, then any portion of the Break-up Fee paid which would otherwise
constitute a usurious interest payment shall instead be treated as a loan by
Licensor to Licensee which is repayable by Licensee upon demand by Licensor, and
not as a usurious interest payment.

          6.     Representations, Warranties and Covenants by Licensor. 
Licensor warrants and represents that:

                  a.     Licensor is the sole owner or licensee of all rights
and interests in the Subject Technology and the related Intellectual Property as
identified on Exhibit A.  No person or entity has any lien, license rights,
option rights, use rights, or other claims or interests in the Subject
Technology and related Intellectual Property.  Licensor has furnished to
Licensee copies of the existing licenses referenced on Exhibit A.

                  b.     There are no other agreements, commitments, or other
rights or obligations which affect the Licensor or the Subject Technology or the
related Intellectual Property which are inconsistent with or conflicting with,
or in violation of, any of the rights or obligations set forth in this
Agreement.

                  c.     There is no pending litigation or, to the knowledge of
Licensor, threatened litigation or factual circumstances which may give rise to
any threatened litigation, affecting the Subject Technology or the Intellectual
Property or the ability of Licensor to enter into and fully perform this
Agreement.

                  d.     Licensor is not aware of any person or entity which is
conducting activities or threatening to conduct activities which would
constitute an infringement of any of the Intellectual Property applicable to the
Subject Technology.

                  e.     The issued patent rights included within the
Intellectual Property applicable to the Subject Technology are in good standing,
with all required maintenance fees and filings applicable thereto being
current. 

                  f.     With respect to the pending patent applications
applicable to the Subject Technology, Licensor is not aware of any facts or
circumstances which may reasonably be expected to impair the ultimate issuance
of patent rights in accordance with the principal claims contained in the
pending patent application.

                  g.     Licensor hereby covenants to furnish to Licensee copies
of all material (1) applications, filings, correspondence and other papers
applicable to the pending patent applications contained with the Intellectual
Property applicable to the Subject Technology, as

5

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

well as (2) any material correspondence, notices or other papers arising after
the effective date of any of the issued patents applicable to the Subject
Technology.  Further, Licensor hereby covenants to furnish to Licensee copies of
all additional papers which Licensor may receive in the future concerning these
patent matters.

                  h.     Licensor makes no representations or warranties of any
kind, either expressed or implied, concerning the validity or scope of any of
the intellectual property rights applicable to the subject technology.  Licensor
makes no representations or warranties of any kind, and Licensor expressly
disclaims any and all implied warranties, as to the ability to make any product
or service utilizing the Subject Technology, or the merchantability or fitness
for any particular purpose of any product or service that may be made from the
Subject Technology.  Licensor makes no representations or warranties, and
Licensor disclaims any implied representations or warranties, to the effect that
the Subject Technology may be commercialized without infringing any patent,
copyright, trademark, or other rights of a third party.  In no event shall
Licensor be liable for any consequential, incidental or special damages, even if
Licensor has been advised of the possibility thereof.

          7.     Term.  The term of this Agreement shall commence as of the
Effective Date set forth in the introductory paragraph of this Agreement, and
shall continue and remain in full force and effect until the last to expire of
any issued patent right applicable to the Subject Technology.  After such
expiration of the term of this Agreement, Licensee shall continue to have the
right to use the Subject Technology on a non-exclusive basis.

          8.     General Provisions.

                  a.     This Agreement shall be construed and enforced in
accordance with the laws of the State of California, excluding the conflicts of
law doctrine.

                  b.     This Agreement constitutes the entirety of the
agreement between the parties with respect to the  matters set forth herein, and
supercedes all prior negotiations and commitments.  Any modification or
amendment to this Agreement shall be effective only if and when it is reduced to
writing and signed by both parties.

                  c.     Each party hereby warrants and represents that it has
full authority and authorization to enter into this Agreement and to fully
perform this Agreement in accordance with its terms, without the need to obtain
any additional approvals, consents or authorizations.  The person signing this
Agreement on behalf of a party hereby warrants and represent that he is duly
authorized to sign and deliver this Agreement on behalf of the party.

                  d.     This Agreement may be signed in multiple, separate
counterparts, all of which shall be treated as one and the same Agreement.  A
party may evidence its execution and delivery of this Agreement by signing this
Agreement and transmitting the signed signature page by facsimile to the other
party.

                  e.     Notices given under this Agreement shall be given in
writing, by any means, including without limitation, U.S. mail, hand delivery,
overnight delivery service, facsimile, electronic mail, or other customary means
of business written communications.

6

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Notice shall be deemed given once it is received at the party’s regular business
address, facsimile number, business email address, or when actually received by
a party’s officer, whichever occurs earlier.  Each party’s initial business
address is set forth at the end of this Agreement.  A party may change its
business address by giving written notice to the other party.

                  f.     This Agreement shall be binding upon and inure to the
benefit of the parties hereto and to their respective successors and assigns.

                  g.     If any litigation or arbitration is commenced to
enforce or construe the terms of this Agreement, the party most prevailing in
said proceedings shall be entitled to recover from the other party all
reasonable attorney’s fees and costs incurred in connection with said
proceedings.

          IN WITNESS WHEREOF, the parties have executed and delivered this
Agreement as of the date set forth above.

 

LICENSEE:

 

 

 

MIXTURE  SCIENCES, INC.

 

 

 

By:

 

 

--------------------------------------------------------------------------------

 

Richard A. Houghten
3550 General Atomics Court
San Diego, CA 92121
858/455-3805
houghtentwo@yahoo.com

 

 

 

LICENSOR:

 

 

 

Astral, Inc.
6175 Lusk Blvd.
San Diego, CA 92121
Telephone: 858/410-5384
Fax: 858/410-5306
troth@allp.com

 

 

 

By:

 

 

--------------------------------------------------------------------------------

 

 

 

          As the Owner of Licensor, Alliance Pharmaceutical Corp. hereby agrees
to the terms of this Agreement.

 

 

ALLIANCE  PHARMACEUTICAL CORP.

 

 

 

By:

 

 

--------------------------------------------------------------------------------

7

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

EXHIBIT A

SUBJECT TECHNOLOGY
INTELLECTUAL PROPERTY – PATENT SUMMARY

Country
Application No.
[Patent No.]

 

Title

 

Date Filed.
Date Issued.

 

Status

 

Owner

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

 

*****
 

 

*****

 

 

16 April 1992

 

 

Issued

 

 

MS

 

*****
 

 

*****

 

 

10 April 1992

 

 

Issued

 

 

MS

 

*****
 

 

*****

 

 

10 April 1992
27 April 1999

 

 

Issued

 

 

MS

 

*****
 

 

*****

 

 

22 December 1994
19 October 1999

 

 

Issued

 

 

MS

 

*****
 

 

*****

 

 

7 January 1998
20 June 2002

 

 

Issued

 

 

TN

 

*****
 

 

*****

 

 

7 January 1997

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

29 June 1999

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

30 November 2001

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

7 January 1998

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

7 January 1998

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

7 January 1998

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

6 July 1998

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

5 September 2000

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

6 July 1999

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

6 July 1999

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

4 June 2001

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

04 June 2001

 

 

Pending

 

 

TN

 

*****
 

 

*****

 

 

09 April 2002

 

 

Pending

 

 

UM

 

*****
 

 

*****

 

 

03 July 2002

 

 

Pending

 

 

UM

 

*****
 

 

*****

 

 

15 March 2002

 

 

Pending

 

 

AS

 

*****
 

 

*****

 

 

20 September 2002

 

 

Pending

 

 

AS

 

*****
 

 

*****

 

 

22 November 1996
20 March 2001

 

 

Issued

 

 

MS

 

*****
 

 

*****

 

 

19 May 1999

 

 

Pending

 

 

MS

 

*****
 

 

*****

 

 

8 March 2001

 

 

Pending

 

 

MS

 

8

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Owner:

 

 

 

 

AS

=

Astral, Inc.

MS

=

Mount Sinai School of Medicine (NY)

TN

=

The University of Tennessee Research Corporation

UM

=

University of Missouri

 

 

 

Licenses:

 

 

a.

Astral has exclusive license rights to the patent rights owned by MS, by way of
a License Agreement dated June 10, 1987.

 

 

b.

Astral expects to obtain exclusive license rights to the patent rights owned by
TN, pursuant to a License Agreement which has been negotiated, drafted and is
ready to be signed.

 

 

c.

Astral expects to obtain exclusive license rights to the patents owned by UM,
pursuant to an existing option agreement, and a License Agreement to be
negotiated.

9

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED
WITH “*****.”  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

EXHIBIT B

Project Plan Expenses
(Up to Three Months)

Category:

 

 

Estimated Costs:

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

 

Personnel compensation, benefits and taxes:
 

$

*****

 

Vendors (animal studies):
 

 

*****

 

Contracts (University of Tennessee):
 

 

*****

 

Patent prosecution:
 

 

*****

 

To be Determined:
 

 

*****

 

 
 

 

*****

 

10